Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) Revenue (2022 - 2026)

TriSalus Life Sciences has reported Revenue over the past 5 years, most recently at $8.9 million for Q1 2026.

  • For Q1 2026, Revenue fell 2.92% year-over-year to $8.9 million; the TTM value through Mar 2026 reached $44.9 million, up 39.64%, while the annual FY2025 figure was $45.2 million, 53.41% up from the prior year.
  • Revenue for Q1 2026 was $8.9 million at TriSalus Life Sciences, down from $13.2 million in the prior quarter.
  • Over five years, Revenue peaked at $13.2 million in Q4 2025 and troughed at $3.0 million in Q1 2023.
  • A 5-year average of $7.3 million and a median of $7.3 million in 2024 define the central range for Revenue.
  • Biggest five-year swings in Revenue: surged 116.39% in 2024 and later fell 2.92% in 2026.
  • Year by year, Revenue stood at $3.2 million in 2022, then skyrocketed by 77.34% to $5.7 million in 2023, then surged by 44.4% to $8.3 million in 2024, then skyrocketed by 59.85% to $13.2 million in 2025, then plummeted by 32.61% to $8.9 million in 2026.
  • Business Quant data shows Revenue for TLSI at $8.9 million in Q1 2026, $13.2 million in Q4 2025, and $11.6 million in Q3 2025.